Antonio Gualberto: I’m starting a new position as Global Head, Due Diligence Oncology at EMD Serono
Antonio Gualberto, Co-Founder at
“I’m happy to share that I’m starting a new position as Global Head, Due Diligence Oncology at EMD Serono, Inc.!”
Antonio Gualberto, serves as the Global Head of Due Diligence, Oncology at EMD Serono, a position he began in January 2025. Antonio is also the Co-Founder of Cavern Therapeutics, a biotech company focused on novel therapies, which he co-founded in 2022.
He was previously the Vice President of External Innovation at BeiGene from April 2024 to January 2025 and has served as an Advisor to CHARM Therapeutics since January 2023. Additionally, he was the Chief Medical Officer at SURGE Therapeutics from March to December 2023.
Earlier in his career, Antonio worked as a Staff Scientist at the University of California, Berkeley and Berkeley National Laboratory from 1995 to 1996. He is currently furthering his expertise at MIT in No-Code AI & Machine Learning (2024).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023